Navacaprant did not statistically significantly improve MADRS total score or SHAPS total score compared with placebo. Topline data were announced from a phase 3 trial evaluating navacaprant for the ...
An analysis of major depressive disorder, covering diagnostic criteria, prevalence statistics across demographics, and ...
Stocktwits on MSN
Biohaven’s phase II depression trial falls short, but analysts downplay impact – Wall Street looks ahead to epilepsy data
Analyst Myles Minter noted that the company’s pivotal Phase III study of BHV-7000 in focal-onset epilepsy in the first half ...
Major depressive disorder (MDD) is a debilitating psychiatric condition characterized by a persistently low mood, a lack of ...
Don't let January get you down. These small changes can help you feel brighter despite the dark days of winter.
Major depressive disorder (MDD) is a leading cause of disability in millions of people worldwide. Importantly, the gut microbiome can contribute to stress-related responses in patients experiencing ...
Spectral speech features may serve as noninvasive biomarkers for monitoring attention and executive function in major depressive disorder.
Long-term outcome research indicates that deep brain stimulation holds promise for the treatment of intractable major /topics/Depression" class="cnnInlineTopic">depression and obsessive-compulsive ...
Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not gotten ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback